Autopsy report · NCT03602898

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

“Insufficient funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Fred Hutchinson Cancer Center

Sponsor type

University, hospital or other

Conditions

Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Myelodysplastic Syndrome

Interventions

Anti-Thymocyte Globulin; Busulfan; Cyclophosphamide; Cyclosporine; Fludarabine Phosphate; Methotrexate

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• PROactive Evaluation of Function to Avoid CardioToxicity
  “Insufficient funding/staff” (90% match in meaning)
• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (87% match in meaning)
• PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
  “Funding unavailable” (87% match in meaning)
• Hatha Yoga in Breast Cancer Survivors
  “Insufficient staff and funding” (87% match in meaning)
• Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment
  “Inadequate funding” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.